Thomas Goss | Senior Vice President
Boston Healthcare Associates Inc

Thomas Goss, Senior Vice President, Boston Healthcare Associates Inc

Thomas Goss has more than 20 years of experience managing and directing healthcare research, including examination of the impact of public and private Payor policy on patient access, assessment of health-related quality-of-life, patient preference, and patient satisfaction associated with healthcare interventions, and evaluation of health economic outcomes associated with healthcare innovations. Tom’s work in health economic assessment includes development of health economic evaluations (cost-effectiveness and budget impact analysis) for multiple markets including the U.S., EU-5, Japan and other markets He also directs disease management program evaluations using patient outcomes data. He has published extensively in these areas and has more than 50 peer-reviewed publications and over 90 peer-reviewed abstracts and invited publications. Prior to joining Boston Healthcare Associates, Dr. Goss was Vice President and Director of Consulting Services at Covance Market Access Services, where he had a 15-year career with increasing levels of responsibility in the areas of client management and executive management. Dr. Goss received a Pharm.D. from the State University of New York at Buffalo, and a B.S. from the Albany College of Pharmacy. He completed graduate course work in Epidemiology, and a postdoctoral fellowship in Pharmacoepidemiology and Outcomes Research at the State University of New York at Buffalo. Dr. Goss has authored chapters in the American College of Clinical Pharmacy Textbook Pharmacoeconomics and Outcomes: Applications for Patient Care and has participated in the ACCP Outcomes and Economics Practice Research Network, and has held memberships and presented at the International Society of Pharmacoeconomics and Outcomes Research and the Academy of Managed Care Pharmacy. Dr. Goss is currently an appointee to the U.S. Center for Medicare & Medicaid Services (CMS) Medicare Evidence Development & Coverage Advisory Committee (MEDCAC).


World Orphan Drug Congress USA 2018 - Conference Day One @ 12:40

Market access challenges and opportunities for orphan and ultra-orphan drugs

  • Looking into the global demand for an evidence-based approach toward orphan drug pricing and reimbursement
  • Current landscape on pharmaceutical practices: undertaking burden of Illness studies, focusing on baseline quality of life, and direct and indirect costs to evaluate orphan drugs and assist with reimbursement
  • Tools to overcome the challenges faced by industry when identifying relevant data sources to document the cost and burden of orphan diseases 
  • Strengths and limitations of available methods of data capture

back to speakers